38 A recent study has unveiled a groundbreaking approach to cancer diagnosis that could revolutionise healthcare accessibility, particularly in resource-limited settings. The new method combines dried serum spots (DSS) with nanoparticle-enhanced laser desorption/ionization mass spectrometry (NPELDI MS). It is a long-lasting, low-cost, and accurate way to find many types of cancer. This new technology has the potential to significantly reduce the rate of undiagnosed cases in areas with limited medical infrastructure. The findings were published in the journal Nature Sustainability. The need for more accessible diagnostic tools is acute, especially in low- and middle-income countries where traditional imaging equipment, like CT scanners, is scarce. The World Health Organization estimates that less than 30% of low-income countries have access to adequate diagnostic facilities. The proposed DSS-NPELDI MS approach could fill this gap by providing an easy-to-use, environmentally friendly solution that requires only minimal resources. Unlike conventional methods, this technique does not depend on costly equipment or cold-chain storage, making it ideal for use in remote and underdeveloped regions. The new diagnostic tool works by analysing metabolic changes in dried serum spots, which are small samples of blood dried on filter paper. The samples are then put through NPELDI MS, a method that uses nanoparticles to make metabolites more ionised, which makes it possible to find and measure them accurately. This method is not only more accessible but also highly sensitive, offering serum-equivalent precision in detecting cancer biomarkers. The study highlights the tool’s efficacy in diagnosing colorectal, gastric, and pancreatic cancers. By implementing this method, the estimated proportion of undiagnosed cases could be dramatically reduced. For colorectal cancer, the rate could drop from 84.30% to 29.20%; for gastric cancer, from 77.57% to 57.22%; and for pancreatic cancer, from 34.56% to 9.30%. These reductions represent a significant improvement in early cancer detection, which is crucial for effective treatment and improved survival rates. One of the key advantages of the DSS-NPELDI MS approach is its sustainability. The method’s reliance on DSS reduces the need for cold storage and complex sample handling, which are major logistical challenges in traditional diagnostics. Moreover, DSS can be stored and transported at room temperature, making it more practical for widespread use. This characteristic also reduces the carbon footprint associated with medical diagnostics, aligning with global efforts to promote sustainable healthcare practices. The economic benefits of this new diagnostic method are equally compelling. The cost of producing DSS and conducting NPELDI MS is relatively low compared to traditional diagnostic tests. The process requires only microlitre volumes of blood, and the materials needed are inexpensive and readily available. This affordability could make comprehensive cancer screening programmes feasible in low-income settings, where healthcare budgets are often constrained. In addition to its economic and environmental advantages, the DSS-NPELDI MS technique offers high diagnostic accuracy. The study’s findings demonstrate that the method can achieve a sensitivity of 82–100% for detecting cancer, comparable to conventional blood-based biomarkers but with the added benefit of requiring less infrastructure and expertise. This high level of accuracy is critical for ensuring reliable diagnostics, especially in regions where medical professionals may lack specialised training. The researchers behind this study advocate for the adoption of DSS-NPELDI MS in global health initiatives aimed at improving cancer detection rates. They argue that the method’s simplicity, affordability, and sustainability make it an ideal tool for enhancing healthcare accessibility and reducing the global cancer burden. But they also acknowledge the need for further research to validate the tool’s effectiveness across different populations and cancer types.